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Abstract
Background: Panitumumab is a fully human antibody against the epidermal growth factor receptor that is
indicated for the treatment of metastatic colorectal cancer (mCRC) after disease progression on standard
chemotherapy. The purpose of this analysis was to examine the immunogenicity of panitumumab and to evaluate
the effect of anti-panitumumab antibodies on pharmacokinetic and safety profiles in patients with mCRC receiving
panitumumab in combination with oxaliplatin- or irinotecan-based chemotherapies.
Methods: Three validated assays (two screening immunoassays and a neutralizing antibody bioassay) were used to
detect the presence of anti-panitumumab antibodies in serum samples collected from patients enrolled in four
panitumumab combination chemotherapy clinical trials. The impact of anti-panitumumab antibodies on
pharmacokinetic and safety profiles was analyzed using population pharmacokinetic analysis and descriptive
statistics, respectively.
Results: Of 1124 patients treated with panitumumab in combination with oxaliplatin- or irinotecan-based
chemotherapy with postbaseline samples available for testing, 20 (1.8%) patients developed binding antibodies and
2 (0.2%) developed neutralizing antibodies. The incidence of anti-panitumumab antibodies was similar in patients
with tumors expressing wild-type or mutant KRAS and in patients receiving oxaliplatin- or irinotecan-based
chemotherapies. No evidence of an altered pharmacokinetic or safety profile was found in patients who tested
positive for anti-panitumumab antibodies.
Conclusions: The immunogenicity of panitumumab in the combination chemotherapy setting was infrequent and
similar to the immunogenicity observed in the monotherapy setting. Panitumumab immunogenicity did not
appear to alter pharmacokinetic or safety profiles. This low rate of immunogenicity may be attributed to the fully
human nature of panitumumab.
Trial registration: ClinicalTrials.gov: NCT00339183 (study 20050181), NCT00411450 (study 20060277), NCT00332163
(study 20050184), and NCT00364013 (study 20050203).
Background
Panitumumab is a high affinity (Kd =5×1 0
11 M) fully
human IgG2 monoclonal antibody (mAb) directed
against human epidermal growth factor receptor (EGFR).
Panitumumab is indicated as monotherapy for the treat-
ment of metastatic colorectal cancer (mCRC) after dis-
e a s ep r o g r e s s i o no nf l u o r o p y r imidine, oxaliplatin, and
irinotecan chemotherapy regimens in the United States
(US) and European Union (EU) [1,2]. In the US,
treatment of patients whose tumors have KRAS muta-
tions in codon 12 or 13 is not recommended [1]. In the
EU, panitumumab is indicated for patients whose tumors
express EGFR and wild-type KRAS [2]. Panitumumab has
been shown to significantly improve progression-free sur-
vival as first-line therapy with FOLFOX4 [3] and as sec-
ond-line therapy with FOLFIRI [4] in patients with
mCRC tumors expressing wild-type KRAS.
An important concern with the administration of thera-
peutic proteins is the potential to induce an immune
response. Immune responses against biologics can affect * Correspondence: mstarcev@amgen.com
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safety (by eliciting injection-site reactions or hypersensitiv-
ity), or reduce efficacy [5]. Therefore, one of the considera-
tions for mAb therapeutic development has been to
reduce the risk of undesirable immunogenicity [6]. Based
on the premise that humanized or fully human mAbs
w o u l db el e s sl i k e l yt oi n d u c ea ni m m u n er e s p o n s et h a n
chimeric or murine-derived mAbs, engineering technolo-
gies have focused on decreasing or eliminating the pre-
sence of nonhuman sequences within the molecule. The
comparison of immunogenicity rates between mAb thera-
peutics is challenging because of differences in dosing regi-
mens, patient populations, and methods used to detect
anti-drug antibodies. Nevertheless, it appears that the
reduction in mouse sequence content has generally
resulted in improved immunogenicity profiles [7], with
only a few examples of fully human mAbs with high inci-
dences of anti-drug antibody development [8,9]. Despite
these advances, the immunogenic potential of a molecule
is difficult to predict based on the protein sequence alone.
Various additional factors may contribute to the overall
immunogenicity risk, including other product characteris-
tics (impurity profile, formulation, post-translational modi-
fications), patient characteristics (eg, pre-existing
immunodeficiency, concurrent illness), and drug adminis-
tration characteristics (frequency, route, and duration) [5].
Cetuximab, an anti-EGFR chimeric mouse-human
monoclonal antibody, had a reportedly low incidence of
anti-chimeric antibodies as measured by a radiometric
assay in early phase clinical trials [10,11]. However, a
high incidence of hypersensitivity reactions consistent
with IgE-mediated anaphylaxis has been observed in
patients treated for mCRC in some areas of the US [12].
These hypersensitivity reactions appeared to be caused
by pre-existing IgE antibodies to galactose-a-1,3-galac-
tose, an oligosaccharide component added during the
production of cetuximab in a mouse cell line by a mur-
ine-specific enzyme [13]. As expected from the apparent
absence of this post-translational modification on panitu-
mumab, hypersensitivity reactions resembling anaphylac-
tic reactions to galactose-a-1,3-galactose have not been
seen in clinical trials or postmarketing reports of patients
receiving panitumumab. Additionally, the presence of
murine-derived N-glycolylneuraminic acid has been
demonstrated on cetuximab, which is introduced by the
manufacturing process [14]. Most or all humans make
antibodies to this sialic acid; these antibodies have been
shown to form immune complexes with cetuximab, but
not panitumumab, in vitro [14].
The fully human nature of panitumumab was expected
to decrease the rate of immunogenicity compared with
therapeutic antibodies containing nonhuman coding
sequences [15]. However, unique sequences in the com-
plementarity determining regions (CDRs) and potential
manufacturing-related modifications still provide the
potential for panitumumab to be recognized as nonself
by the human immune system, which could result in the
development of anti-panitumumab antibody responses.
As it is not known whether these immune responses
could lead to clinically serious outcomes, the monitoring
of patients who participated in clinical trials for the
development of antibodies and an assessment of the
impact of anti-panitumumab antibodies on pharmacoki-
netics and safety was a critical component of the panitu-
mumab clinical development program.
The immunogenicity of panitumumab when adminis-
tered as monotherapy was evaluated in clinical trials of
patients with mCRC and other solid tumors. The inci-
dence of binding antibodies to panitumumab (excluding
predose and transient positive patients) was < 1% as
detected by the acid dissociation enzyme-linked immu-
nosorbent assay (ELISA) [16] and 4.6% as detected by the
Biacore
® assay [1,16]. The incidence of neutralizing anti-
bodies was 1.6%. The analysis described here examined
the immunogenicity of panitumumab when administered
as combination therapy with oxaliplatin- or irinotecan-
based chemotherapy regimens in patients with refractory
mCRC and explored the relationship between panitumu-
mab immunogenicity and pharmacokinetic and safety
profiles.
Methods
Patients and sample collection
Serum samples for anti-panitumumab antibody testing
were collected from mCRC patients enrolled in 4 panitu-
mumab clinical trials (20050184, 20060277, 20050181,
and 20050203). Patients in these studies received irinote-
can-based (including FOLFIRI) or oxaliplatin-based
(FOLFOX) chemotherapies with or without panitumu-
mab. Study 20050184 (STEPP) was a phase 2, open-label,
randomized trial to compare pre-emptive skin toxicity
therapy with reactive treatment in patients with mCRC
receiving panitumumab plus irinotecan or FOLFIRI [17].
Study 20060277 (PRECEPT) was a phase 2, open-label,
single-arm trial that estimated the effect of tumor KRAS
status (wild-type or mutant) on efficacy endpoints in
patients receiving panitumumab plus FOLFIRI as sec-
ond-line therapy for mCRC [18]. Study 20050181 was a
phase 3 randomized trial to evaluate panitumumab plus
FOLFIRI combination therapy versus FOLFIRI alone as
second-line therapy for mCRC [4]. Study 20050203
(PRIME) was a phase 3, randomized trial to evaluate the
efficacy and safety of panitumumab in combination with
FOLFOX4 versus FOLFOX4 alone as first-line therapy
for mCRC [3]. Panitumumab was administered at
6.0 mg/kg every 2 weeks (Q2W) in all studies; patients in
one arm of study 20050184 received panitumumab at
9.0 mg/kg every 3 weeks.
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genicity assessments were collected from all panitumu-
mab-treated patients prior to study treatment (baseline
samples) and from all patients at the safety follow-up visit
(postbaseline samples, obtained 30 ± 3 days after the
administration of the last study treatment). Serum samples
used for the measurement of panitumumab concentration
(pharmacokinetic assessments) were collected from
patients enrolled in study 20050181 before dosing on cycle
1 day 1 and cycle 2 day 1, every 8 weeks starting at week
8, and at the safety follow-up visit (30 ± 3 days after
administration of the last dose).
KRAS mutation status was determined using DNA iso-
lated from fixed tumor samples. Mutations in KRAS were
detected using a KRAS mutation kit (DxS Ltd, Manchester,
UK) as previously described [19]. KRAS status was avail-
able from 87 (95%) patients in study 20050184, 109 (95%)
patients in study 20060277, 1083 (91%) patients in study
20050181, and 1096 (93%) patients in study 20050203.
Patients receiving both doses of panitumumab (6.0 mg/
kg Q2W and 9.0 mg/kg Q3W) were included in the
immunogenicity and safety analyses.
These studies were conducted in accordance with the
principles for human experimentation as defined in the
International Conference on Harmonization Good Clinical
Practice guidelines and the principles of the Declaration of
Helsinki. All studies were approved by the corresponding
Investigational Review Boards, and informed consent was
obtained from each patient after being advised of the
potential risks and benefits as well as the investigational
nature of the study.
Anti-panitumumab antibody detection assays
Antibody samples were evaluated for the presence of anti-
panitumumab antibodies according to the testing strategy
depicted in Figure 1. The screening assays used to detect
antibodies capable of binding to panitumumab, an ELISA
and a Biacore assay, have been previously described [16].
All samples confirmed to be positive in either screening
assay were further tested for antibodies capable of neutra-
lizing the activity of panitumumab in vitro in a cell-based
EGFR phosphorylation bioassay as previously described
[16]. Immunogenicity assay characteristics are shown in
Table 1. Developing antibodies were defined as antibodies
that were observed only at a postbaseline time point(s) but
not at the baseline time point. Pre-existing antibodies
were defined as antibodies that were observed at the base-
line time point.
The assays and sample collection strategy were opti-
mized to reduce drug interference with antibody detec-
tion. The performance of the immunogenicity assays was
monitored by implementing a trending process utilizing
Westgard multirules that tracked negative control and
positive control values for each assay performed [20].
The observed low incidences of trending alarms and
assay failures in the screening immunoassays and bioas-
say were indicative of assay stability.
Serum panitumumab concentration immunoassay
Panitumumab concentrations in human serum were mea-
sured by a validated ELISA. Briefly, panitumumab was
captured in microplate wells precoated with mouse anti-
panitumumab antibody (Amgen Inc., Thousand Oaks, CA,
USA). Horseradish peroxidase-labeled rabbit polyclonal
anti-panitumumab antibody (Amgen Inc.) was added to
the wells and allowed to react with the captured panitu-
mumab. A colorimetric signal was produced after the
addition of tetramethylbenzidine-peroxidase substrate
solution. The optical density (OD) of the signal, measured
at 450-650 nm, was proportional to the amount of cap-
tured panitumumab. The conversion of OD units to con-
centrations for the assay quality controls and samples was
achieved through a computer software-mediated compari-
son to a standard curve on the same assay run, which was
regressed according to a 5 PL (Auto Estimate) regression
model with a weighting factor of 1/Y. The lower limit of
quantitation was 400 ng/mL in human serum.
Impact of immunogenicity on panitumumab
pharmacokinetics
A population pharmacokinetic (PopPK) modeling and
simulation approach was performed to evaluate the impact
of immunogenicity on panitumumab pharmacokinetics by
comparing the observed panitumumab concentrations of
antibody-positive patients from study 20050181 with the
predicted pharmacokinetic profiles based on PopPK para-
meters for antibody-negative patients.
A 2-compartment model with parallel linear and non-
linear (Michaelis-Menten) elimination pathways has been
used to describe the disposition of panitumumab [21,22].
A previously developed and validated PopPK model [21]
was updated by including the pharmacokinetic data from
antibody-negative patients in study 20050181. The predic-
tive check [23] was used to evaluate the validity of the
updated PopPK model before subsequent analyses were
performed. Using the updated PopPK parameters for anti-
body-negative patients, 1000 pharmacokinetic profiles
were simulated for each antibody-positive patient accord-
ing to the actual individual dosing history. The observed
concentrations from each antibody-positive patient were
superimposed with the model-predicted distribution. The
pharmacokinetics of panitumumab in antibody-positive
patients would be considered similar to antibody-negative
patients if the proportions of the observed concentrations
from antibody-positive patients falling within and outside
the 90% prediction interval were not statistically different
(chi-square test; a < 0.05) from hypothesized proportions,
i e ,5 %a b o v e ,5 %b e l o w ,a n d9 0 %w i t h i nt h ei n t e r v a l .A
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mum difference in panitumumab concentration between
antibody-positive and antibody-negative patients that,
given the available sample size, could be statistically
significant.
Impact of immunogenicity on panitumumab safety
The impact of immunogenicity on safety was evaluated
through the review and assessment of the incidence of
adverse events, potential infusion reactions, reasons for
discontinuation from therapy, and total number of doses
received while on study for panitumumab-treated anti-
body-positive patients and anti-panitumumab antibody-
negative patients.
Results
Patients
A total of 1325 patients were tested for anti-panitumu-
mab antibodies, including 558 patients who were treated
with panitumumab plus oxaliplatin-based chemotherapy
Figure 1 Panitumumab immunogenicity testing strategy. Three validated assays were used to detect the presence of anti-panitumumab
antibodies. All clinical study samples were tested in two screening immunoassays (an acid-dissociation ELISA and a Biacore-based biosensor
assay) to detect antibodies capable of binding to panitumumab. Samples that tested above the assay threshold and demonstrated reduction in
response in the drug-competition specificity assay were reported as positive for binding antibodies and tested further in a cell-based neutralizing
antibody bioassay. Assay thresholds were based on the upper bound of a one-sided 95% reference interval for the distribution of signals
generated by serum samples from healthy subjects or cancer patients. S/N, signal-to-noise ratio.
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mumab plus irinotecan-based chemotherapy (studies
20050181, 20050184, and 20060277). Of these, 1225
patients (511 treated with panitumumab plus oxaliplatin
and 714 treated with panitumumab plus irinotecan) had
baseline samples available and 1124 patients (480 treated
with panitumumab plus oxaliplatin and 664 treated with
panitumumab plus irinotecan) had postbaseline samples
available for testing. Over half of the patients were men
and the population was predominantly white. Overall,
53% of the patients had tumors expressing wild-type
KRAS (39% had mutant KRAS and 8% were unevaluable).
Anti-panitumumab antibodies
The development of anti-panitumumab antibodies in
patients receiving panitumumab in combination with che-
motherapy (oxaliplatin- or irinotecan-based) occurred
infrequently: 1.8% of patients developed binding antibodies
and 0.2% of patients developed neutralizing antibodies
(Table 2). The incidence of developing antibodies was low
Table 1 Immunogenicity assay characteristics
Drug Tolerance
†
Assay Assay Sensitivity* LLRD Anti-panitumumab Panitumumab
ELISA 10 ng/mL 60 ng/mL 60 ng/mL
500 ng/mL
9 μg/mL
81 μg/mL
Biacore 1.8 μg/mL 1.8 μg/mL 4 μg/mL
20 μg/mL
1.9 μg/mL
7.8 μg/mL
Bioassay ~62.5 ng/mL ~125 ng/mL ~1 μg/mL ~2.5 μg/mL
*Intersection of the assay threshold with the rabbit polyclonal anti-panitumumab antibody dose-response curve.
†Level of anti-panitumumab antibodies that can be detected in the presence of the amount of panitumumab in the adjacent column.
LLRD, lower limit of reliable detection, the lowest concentration of the rabbit polyclonal anti-panitumumab antibody that could be reliably detected as positive
when spiked into neat serum from multiple donors.
Table 2 Incidence of anti-panitumumab antibodies
Wild-Type KRAS Mutant KRAS All Patients*
Either Biacore or ELISA Bioassay Either Biacore or ELISA Bioassay Either Biacore or ELISA Bioassay
Total Antibody Incidence, n1/n2 (%)
20050184 6/48 (12.5) 1/48 (2.1) 0/37 (0) 0/37 (0) 6/93 (6.5) 1/93 (1.1)
20060277 0/64 (0) 0/64 (0) 1/45 (2.2) 1/45 (2.2) 1/115 (0.9) 1/115 (0.9)
20050181 11/288 (3.8) 0/288 (0) 9/223 (4.0) 1/223 (0.4) 22/559 (3.9) 1/559 (0.2)
20050203 (Pmab + OX) 21/308 (6.8) 3/308 (1.0) 10/206 (4.9) 1/206 (0.5) 36/558 (6.5) 4/558 (0.7)
Pmab + IRI 17/400 (4.3) 1/400 (0.3) 10/305 (3.3) 2/305 (3.3) 29/767 (3.8) 3/767 (0.4)
Pmab + IRI or OX 38/708 (5.4) 4/708 (0.6) 20/511 (3.9) 3/511 (0.6) 65/1325 (4.9) 7/1325 (0.5)
Pre-existing Antibody Incidence, n3/n4 (%)
20050184 4/48 (8.3) 1/48 (2.1) 0/37 (0) 0/37 (0) 4/93 (4.3) 1/93 (1.1)
20060277 0/64 (0) 0/64 (0) 1/45 (2.2) 1/45 (2.2) 1/115 (0.9) 1/115 (0.9)
20050181 11/252 (4.4) 0/252 (0) 7/210 (3.3) 1/210 (0.5) 19/506 (3.8) 1/506 (0.2)
20050203 (Pmab + OX) 11/282 (3.9) 2/282 (0.7) 7/188 (3.7) 0/188 (0) 22/511 (4.3) 2/511 (0.4)
Pmab + IRI 15/364 (4.1) 1/364 (0.3) 8/292 (2.7) 2/292 (0.7) 24/714 (3.4) 3/714 (0.4)
Pmab + IRI or OX 26/646 (4.0) 3/646 (0.5) 15/480 (3.1) 2/480 (0.4) 46/1225 (3.8) 5/1225 (0.4)
Developing Antibody Incidence, n5/n6 (%)
20050184 2/37 (5.4) 0/37 (0) 0/26 (0) 0/26 (0) 2/68 (2.9) 0/68 (0)
20060277 0/42 (0) 0/42 (0) 0/30 (0) 0/30 (0) 0/75 (0) 0/75 (0)
20050181 0/255 (0) 0/255 (0) 3/205 (1.5) 0/205 (0) 4/501 (0.8) 0/501 (0)
20050203 (Pmab + OX) 10/264 (3.8) 1/264 (0.4) 3/178 (1.7) 1/178 (0.6) 14/480 (2.9) 2/480 (0.4)
Pmab + IRI 2/334 (0.6) 0/334 (0) 3/261 (1.1) 0/261 (0) 6/644 (0.9) 0/644 (0)
Pmab + IRI or OX 12/598 (2.0) 1/598 (0.2) 6/439 (1.4) 1/439 (0.2) 20/1124 (1.8) 2/1124 (0.2)
*All Patients includes patients with wild-type, mutant, and unknown KRAS status.
Pmab, panitumumab; IRI, irinotecan-based chemotherapy; OX, oxaliplatin-based chemotherapy; n1, number of patients with a positive antibody result at any time
point; n2, number of patients with at least one immunoassay result; n3, number of patients with a positive antibody result at or before baseline; n4, number of
patients with an immunoassay antibody result at or before baseline; n5, number of patients with negative or no antibody result at or before baseline and a
positive antibody result at a postbaseline time point; n6, number of patients with at least one postbaseline immunoassay antibody result
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KRAS (2.0% and 1.4% binding antibodies and 0.2% and
0.2% neutralizing antibodies, respectively). The incidence
of developing antibodies was low in patients treated with
oxaliplatin-based chemotherapy (2.9% binding antibodies
and 0.4% neutralizing antibodies) and in patients treated
with irinotecan-based chemotherapy (0.9% binding antibo-
dies and 0% neutralizing antibodies). Pre-existing binding
and neutralizing antibodies were detected in 3.8% and
0.4% of all patients before the start of any investigational
product, respectively.
Impact of immunogenicity on panitumumab
pharmacokinetics
Of the 22 patients with pre-existing and post-treatment
developing anti-panitumumab antibodies in study
20050181, 38 samples from 11 patients were available for
evaluation of panitumumab concentration. In addition, 68
samples from 53 antibody-negative patients in study
20050181 were analyzed for panitumumab concentration.
Because of the low rate of immunogenicity in study
20050181 and limited availability of pharmacokinetic sam-
ples, the concentration data from patients with pre-existing
and post-treatment developing antibody responses were
combined for analysis.
Among 38 observed concentrations from the antibody-
positive patients, 2 (5%) were below, 5 (13%) were above,
and 31 (82%) were within the 90% prediction interval
derived from pharmacokinetic profiles of antibody-negative
patients. The proportions were not statistically different
(P = 0.0685) from the hypothesized proportions (Table 3)
and were similar to those for the antibody-negative patients
(P = 0.8807), suggesting that no marked difference in the
observed panitumumab concentrations was observed
between the antibody-positive and antibody-negative
patients.
Results of the sensitivity analysis showed that a statisti-
cally significant effect of immunogenicity would have been
observed if the serum concentrations of antibody-positive
patients were at least 55% lower than the current observed
values given the current sample size. To further evaluate
the impact of the sample size on the analysis, additional
analyses were performed and the results showed that 200
and 650 samples would be needed to detect a 38% and
20% difference in panitumumab serum concentration,
respectively (Figure 2).
Impact of immunogenicity on panitumumab safety
profiles
No apparent difference in the rate of grade 3 and grade 4
adverse events (as graded per National Cancer Institute
Common Terminology Criteria for Adverse Events [NCI
CTCAE] version 3.0) was observed between patients who
tested positive for anti-panitumumab antibodies and those
who tested negative (Table 4). Although the incidence of
grade 5 events was higher in patients testing positive for
developing antibodies (n = 4; 19%) than in antibody-nega-
tive patients (n = 82; 6%), following a medical review of
these cases, all were reported in the setting of progression
of the underlying disease. The number of chemotherapy
cycles received varied among patients; no apparent rela-
tionship between antibody status and number of cycles
received was observed. Three patients experienced infu-
sion reactions deemed related to panitumumab. Two
patients (1 predose-positive and 1 developing antibody-
positive) experienced grade 1 (mild) infusion reactions
reported as vomiting and fever. One patient (predose-posi-
tive) had a grade 2 (moderate) infusion reaction of hyper-
sensitivity, which was reported on study day 272 following
multiple administrations of panitumumab. The event of
hypersensitivity was confounded by the coadministration
of oxaliplatin. Although thea n a l y s i so ft h ei m p a c to f
immunogenicity on safety was limited by the small num-
ber of antibody-positive patients, there was no evidence of
an altered safety profile found in patients who tested posi-
tive for pre-existing or post-treatment developing anti-
panitumumab antibodies compared to the safety profile of
those patients who tested negative.
Discussion
The panitumumab immunogenicity testing strategy uti-
lized two validated screening immunoassays to detect the
presence of all antibodies capable of binding to panitu-
mumab. The screening immunoassays were chosen to
provide the optimal combination of sensitivity and drug
tolerance (ELISA) and the ability to detect antibodies of
various affinities (Biacore) [16]. A cell-based bioassay was
used to detect antibodies with neutralizing activity.
Table 3 Distribution of the observed concentrations of panitumumab relative to the 90% predictive interval
Distribution in Relation to 90% Prediction Interval Antibody-Positive Patients Antibody-Negative Patients P-value
†
N % 95% CI P-value* N % 95% CI P-value*
Below 2 5.3 0.6 -17.8 0.07 3 4.4 0.9 - 12.4 0.13 0.88
Above 5 13.2 4.4 - 28.1 7 10.3 4.2 - 20.1
Within 31 81.6 65.7 - 92.3 58 85.3 74.6 - 92.7
*Chi-square test with hypothesized proportions (5% below, 5% above, 90% within).
†Chi-square test of antibody-positive proportion vs antibody-negative proportion.
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the development of anti-panitumumab antibodies in
combination chemotherapy patients was detected infre-
quently. Developing antibody incidences did not appear
to be affected by tumor KRAS status (wild-type or
mutant) or combination chemotherapy regimen (oxali-
platin- or irinotecan-based).
Pre-existing binding and neutralizing antibodies were
detected prior to the administration of panitumumab in
3.8% and 0.4% of patients, respectively. Positive results
from these baseline samples may be due to the presence of
cross-reacting antibodies generated against antigens that
share a similar epitope with panitumumab. The presence
of pre-existing antibodies in panitumumab-treated
patients did not appear to affect the postdose antibody
state of these patients. In addition, patients who tested
positive for pre-existing antibodies did not appear to have
altered safety profiles.
The broad, nonspecific cytotoxic effects of chemother-
apy have the potential to impair the immune system,
which could reduce the incidence of anti-panitumumab
antibodies in patients receiving panitumumab in
combination with chemotherapy. Both oxaliplatin and
irinotecan have gastrointestinal toxicities [24,25], and
have the potential to affect local and systemic immunity.
The effects of chemotherapy on acquired immunity may
have affected the development of anti-panitumumab
antibodies in patients receiving chemotherapy plus pani-
tumumab. The incidence of binding antibodies in the
monotherapy setting (excluding predose and transient
positive patients) was 3/613 (< 1%) as detected by the
acid dissociation ELISA and 28/613 (4.6%) as detected
by the Biacore assay [1], and neutralizing antibodies
were detected in 10/613 (1.6%) of the patients [1]. The
incidence of developing binding and neutralizing antibo-
dies in the combination chemotherapy setting described
here was similar but slightly lower (1.0% as detected by
the ELISA, 0.8% as detected by the Biacore assay and
0.2% as detected by the neutralizing assay).
Based on available pharmacokinetic data from study
20050181, the phase 3 study of panitumumab plus FOL-
FIRI for second-line treatment of mCRC, no evidence of
an altered panitumumab pharmacokinetic profile was
found in patients who received panitumumab 6.0 mg/kg
Figure 2 Sensitivity analysis. The sensitivity analysis estimated the minimum difference in panitumumab concentration between antibody-
positive and antibody-negative samples that could be statistically significant (P < 0.05) with respect to the model prediction. Results show that
the current observed sample size for pharmacokinetic testing (n = 38) from antibody-positive patients was only adequate to detect a difference
of > 55%. Approximately 200 and 650 samples from antibody-positive patients would be required to detect differences of 38% and 20%,
respectively.
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anti-panitumumab antibodies. The results from study
20050181 were in agreement with previously published
observations that there were no apparent differences in
steady-state AUC, Cmax,a n dC min between patients who
developed anti-panitumumab antibodies and those who
did not [21,22]. A sensitivity analysis was conducted to
show that even though the pharmacokinetic data were
limited, a statistically significant effect of immunogenicity
would have been observed if the difference in serum con-
centrations between antibody-positive and antibody-nega-
tive patients was greater than 55%. Therefore, this analysis
ruled out the possibility that immunogenicity would cause
a > 55% decrease in the panitumumab serum concentra-
tions. Since the relationship between pharmacokinetics
and efficacy has not been established, it is unclear what
level of decrease in panitumumab serum concentration
would result in a change in efficacy. By assuming a < 20%
difference would be biologically unimportant, additional
simulations were conducted to understand the sample size
required to detect that level of difference. The result
suggested that approximately 650 samples from antibody-
positive patients would be required to detect a 20% differ-
ence in pharmacokinetics. To obtain this larger number of
samples, it would require either fewer samples (ie, sparse
sampling) from a larger antibody-positive population or
more samples (ie, intensive sampling) from a smaller anti-
body-positive population, both of which would be challen-
ging, considering the low rate of immunogenicity for
panitumumab.
Overall, there did not appear to be an association
between the development of antibodies and safety out-
comes. Higher incidences of adverse events observed in
patients who were antibody negative at baseline and devel-
oped antibodies during the conduct of the study (n = 21)
compared with those who were antibody negative
throughout the study (n = 1317) may be related to the
s m a l ls a m p l es i z e .G r a d e5e v ents in antibody-positive
patients occurred in the setting of disease progression, and
serious adverse events were similar in type and nature to
those reported in patients who did not develop anti-pani-
tumumab antibodies.
Although panitumumab was expected to have a low
rate of immunogenicity compared to therapeutic antibo-
dies containing nonhuman coding sequences, unique
sequences in the CDRs could still be immunogenic. An
in silico analysis to evaluate the potential risk of panitu-
mumab sequence-associated immunogenicity suggested
that panitumumab light and heavy chains do not contain
any non-tolerant agretopes predicted to be able to bind
to the eight most common HLA-DRB1 alleles. The low
risk of panitumumab immunogenicity was confirmed by
Table 4 Summary of adverse events (safety analysis set*)
Antibody
Negative
(N = 1317)
Antibody
Positive
(N = 65)
Predose
Positive
(N = 46)
Developing Antibody
Positive
(N = 21)
Patients with any adverse event
†, n (%) 1312 (100) 65 (100) 46 (100) 21 (100)
Worst grade of 3
‡ 716 (54) 26 (40) 18 (39) 8 (38)
Worst grade of 4
‡ 264 (20) 18 (28) 15 (33) 4 (19)
Worst grade of 5
‡ 82 (6) 6 (9) 2 (4) 4 (19)
Any serious adverse event 544 (41) 32 (49) 23 (50) 10 (48)
Patients with any adverse event leading to permanent discontinuation of
any study drug, n (%)
299 (23) 16 (25) 8 (17) 8 (38)
Not serious 217 (16) 12 (18) 6 (13) 6 (29)
Serious 108 (8) 6 (9) 3 (7) 3 (14)
Patients with any treatment-related adverse event
§, n (%) 1298 (99) 65 (100) 46 (100) 21 (100)
Worst grade of 3
‡ 739 (56) 30 (46) 20 (43) 11 (52)
Worst grade of 4
‡ 204 (15) 15 (23) 13 (28) 2 (10)
Worst grade of 5
‡ 13 (1) 1 (2) 0 1 (5)
Any serious adverse event 314 (24) 20 (31) 14 (30) 6 (29)
Patients with any adverse event leading to permanent discontinuation of
any study drug, n (%)
251 (19) 11 (17) 5 (11) 6 (29)
Not serious 200 (15) 9 (14) 4 (9) 5 (24)
Serious 64 (5) 2 (3) 1 (2) 1 (5)
*The safety analysis set included all patients who were enrolled, randomized, and received at least one dose of study treatment in studies 20050203, 20050181,
20050184, and 20060277. Patients not testing positive by ELISA, Biacore, and bioassay or with all antibody results missing were included.
†Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 12.0.
‡Severity was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, with the exception of some dermatology/skin adverse
events, which were graded using CTCAE version 3.0 with modifications. Fatal adverse events were classified as grade 5.
§The investigator considered there to be a reasonable possibility that the event may have been caused by study drug.
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motherapy clinical trials, which indicated that patients
treated with panitumumab in combination with irinote-
can- or oxaliplatin-based chemotherapy infrequently
developed antibodies against panitumumab.
Conclusions
In summary, the immunogenicity of panitumumab in the
combination chemotherapy setting was infrequent and
was similar to the immunogenicity observed in the mono-
therapy setting. This low rate of immunogenicity may be
attributed to the fully human nature of panitumumab.
Additionally, the presence of anti-panitumumab antibodies
did not appear to alter pharmacokinetic or safety profiles
of panitumumab.
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